News : orexo

Orexo’s drug discovery collaboration terminated and OX-CLI/OX-ESI projects end

1/31/2012 2:30 AM EST - Orexo

Uppsala – January 31, 2012 - Orexo AB and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV ("Janssen"), have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program. Each party has regained all commercial rights for its respective drug discovery programs.

Hence,...

Positive study results for OX27

12/20/2011 7:00 AM EST - Orexo

Uppsala - December 20, 2011 - Orexo AB (STO: ORX) has obtained positive results in a pharmacokinetic study with the OX27 project. The study was conducted on healthy subjects, with the aim to demonstrate that OX27 has the potential for more flexible dosing than fentanyl based products.

OX27 is a sublingual (under the tongue) tablet, developed to improve the treatment of breakthrough pain in cancer patients. The...

Orexo and Uppsala University receive Swedish Research Council grant for bioceram...

11/30/2011 2:00 AM EST - Orexo

Uppsala, November 30 2011 - Orexo AB (STO: ORX) has been awarded a 2.1 million SEK grant from the Swedish Research Council for the project "Bioceramic materials for slow release of potent drugs". The project will be conducted between 2012 and 2015 in collaboration with a research team, led by Professor Håkan Engqvist, Applied Materials Science, Department of Engineering Sciences at Uppsala University.

Interim report, January-September 2011

11/9/2011 2:00 AM EST - Orexo

Uppsala, November 9, 2011 - Orexo´s proprietary development programs advance
For the period

· Net revenues totaled to MSEK 142.9 (101.4).
· Loss after tax was MSEK 121.0 (loss: 91.4).
· Cash flow from operating activities showed a loss of MSEK 70.3 (loss: 13.7).
· Loss per share was SEK 4.61 (loss: 3.90).
· Cash and cash equivalents at the end of the period totaled MSEK 294.3 compared with MSEK 135.8 at...

Nomination Committee prior to Orexo’s Annual General Meeting 2012 and Financial ...

10/11/2011 2:00 AM EST - Orexo

At Orexo’s Annual General Meeting on April 7, 2011, it was resolved that the company shall have a Nomination Committee consisting of one representative for each of the four largest shareholders, in terms of the number of votes, and the Chairman of the Board of Directors.

The Nomination Committee, whose tasks include providing proposals to the General Meeting regarding Chairman of the Meeting, Board members,...

Orexo appoints Peter Edman as Chief Scientific Officer

10/4/2011 3:00 AM EST - Orexo

Uppsala, Sweden, October 4, 2011 - Orexo AB (STO: ORX) appoints Peter Edman as Chief Scientific Officer. Peter Edman’s long experience from all phases of drug development and his extensive scientific background makes him particularly well suited for assuming the overall responsibility for Orexo’s research and development.

Peter Edman holds a PhD and Associate Professor title in Biochemistry and has since 2008 been...

Orexo announces positive results supporting OX219 for treatment of opioid depend...

9/21/2011 2:00 AM EST - Orexo

Uppsala, Sweden, September 21, 2011 – Orexo AB (STO: ORX) today announced that it has obtained positive results in a clinical study with OX219, which is being developed for the treatment of opioid dependence. The study was designed to decide the commercial formulation and dose for OX219.

Orexo has consulted with the FDA to define the optimal development path for OX219, and will plan to pursue a final drug...

Orexo strengthens its commercial knowhow and appoints Nikolaj Sørensen as Chief ...

9/16/2011 4:30 AM EST - Orexo

Uppsala, Sweden, September 16, 2011 - Orexo AB (STO: ORX) appoints Nikolaj Sørensen as Chief Commercial Officer effective October 1, 2011. Nikolaj has extensive experience of the pharmaceutical industry and will be responsible for Orexo’s commercial operations as well as development of the company’s commercial strategies. His international commercial experience is a key asset in Orexo’s goal to develop, market and...

Orexo appoints Carl-Johan Blomberg as new Chief Financial Officer

8/31/2011 5:15 AM EST - Orexo

Uppsala, Sweden, August 31, 2011 – Orexo AB (STO: ORX) appoints Carl-Johan Blomberg as new Chief Financial Officer, effective September 1. Carl-Johan Blomberg will take overall responsibility for the Group's Finance and Administration function, including IR and IT and will be part of the executive management team.

Carl-Johan has many years extensive experience in Finance from various industries, such as...

Changes in ownership in Orexo AB – new number of shares and votes

7/29/2011 8:00 AM EST - Orexo

Uppsala, July 29, 2011 - Following the successful completion of the rights issue providing gross proceeds of approximately MSEK 245 in June 2011, Orexo is pleased to announce the resulting significant changes in ownership as well as number of shares.

As per July 29, 2011 the total number of shares and votes in Orexo amounts to 29,850,940, which corresponds to an increase by 6,438,188 shares.

A key objective of the...

Found press releases